Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sarepta Therapeutics
(NQ:
SRPT
)
146.35
+0.74 (+0.51%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sarepta Therapeutics
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
1 Top Growth Stock to Buy and Hold for 10 Years
May 01, 2024
This company's lineup might look very different in a decade, but the end result will be the same for investors.
Via
The Motley Fool
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 30, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Stock Shows Improved Technical Strength
April 29, 2024
The Relative Strength (RS) Rating for Sarepta Therapeutics stock headed into a new percentile Monday, as it got a lift from 70 to 73.
Via
Investor's Business Daily
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
April 24, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics: Q4 Earnings Insights
February 28, 2024
Via
Benzinga
A Preview Of Sarepta Therapeutics's Earnings
February 27, 2024
Via
Benzinga
Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst
April 08, 2024
Sarepta stock has taken a beating this year, and it might not be over with the first-quarter report looming.
Via
Investor's Business Daily
2 Biotech Stocks to Buy Hand Over Fist in April
April 06, 2024
These drugmakers have made important moves over the past year.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
April 04, 2024
Via
Benzinga
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 29, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback
March 28, 2024
The company could follow Sarepta Therapeutics with a gene therapy for Duchenne muscular dystrophy.
Via
Investor's Business Daily
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
March 13, 2024
The threat is still emerging, but it could be significant.
Via
The Motley Fool
This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO
March 08, 2024
REGENXBIO's promising gene therapy advancements! RBC Capital Markets upgraded REGENXBIO (RGNX), citing impressive RGX-202 trial results in Duchenne patients.
Via
Benzinga
Got $1,000? Buy These Hot Growth Stocks Before They Take Off.
March 08, 2024
These stocks haven't been able to get much traction lately, even though they clearly deserve to now.
Via
The Motley Fool
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst
March 04, 2024
The upcoming regulatory decision on its latest drug could be big.
Via
The Motley Fool
Sarepta Therapeutics to Present at Upcoming Investor Conferences
March 04, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 29, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
February 29, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript
February 29, 2024
SRPT earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
February 28, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Is It Too Late to Buy Sarepta Therapeutics Stock?
February 28, 2024
The company's hyperfocus on its core area could continue to be highly lucrative.
Via
The Motley Fool
Earnings Scheduled For February 28, 2024
February 28, 2024
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion.
Via
Benzinga
Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices
February 26, 2024
Latest pharmaceutical trends in the U.S. as drug prices surged 35% in 2023. Uncover insights into the industry's focus on rare diseases, escalating costs, and the impact on FDA-approved drugs.
Via
Benzinga
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
February 21, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
February 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
February 19, 2024
Via
Benzinga
FDA Fast-Tracks Review Of Sarepta's Groundbreaking Muscular Dystrophy Treatment With $1B Market In Sight
February 16, 2024
Sarepta's Elevidys efficacy supplement accepted for Duchenne muscular dystrophy treatment expansion, potential $1 billion yearly opportunity. FDA review goal: June 21, 2024.
Via
Benzinga
Exposures
Product Safety
Why DoorDash Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Friday's Mid-Day Session
February 16, 2024
Shares of DoorDash, Inc. (NASDAQ: DASH) fell sharply in today’s session as the company reported mixed financial results for its fourth quarter.
Via
Benzinga
Why Sarepta Therapeutics Stock Is Soaring Today
February 16, 2024
The biotech just scored a big FDA win with an even bigger one potentially coming by June.
Via
The Motley Fool
Exposures
Product Safety
Applied Materials Posts Upbeat Earnings, Joins Texas Roadhouse, Vulcan Materials And Other Big Stocks Moving Higher On Friday
February 16, 2024
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Friday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.